| Author (Person) | Dyer, Geoff |
|---|---|
| Series Title | Financial Times |
| Series Details | 28.10.03, p32 |
| Publication Date | 28/10/2003 |
| Content Type | News |
|
The Chief Executive of Serono, Europe's leading biotechnology company, has described the European Union's process for approving new drugs a 'farce' that was helping to drive the industry to the United States. His remarks were prompted by the European Agency for the Evaluation of Medicinal Products' decision in April 2003 to turn down Serono's Serostim drug for Aids-related wasting. The drug has been available in the US since 1996. |
|
| Related Links |
|
| Subject Categories | Business and Industry, Health |
